Premium
Targeting plasma cells with daratumumab aids in the treatment of post‐transplant autoimmune‐like hepatitis
Author(s) -
Epperly Rebecca,
Santiago Teresa,
Morin Cara E.,
Patton Kurt,
Deyo Jeff,
Eshun John,
Triplett Brandon,
Sharma Akshay
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.29290
Subject(s) - medicine , daratumumab , autoimmune hepatitis , immunology , hepatitis , virology , oncology , intensive care medicine , antibody , monoclonal antibody
Antibody‐mediated autoimmune‐like hepatitis is a rare and challenging occurrence after hematopoietic cell transplant (HCT). We present the case of a 16‐year‐old male patient with Ph+ ALL who underwent matched sibling donor HCT and developed autoimmune‐like hepatitis after receiving ponatinib for post‐HCT maintenance, evidenced by marked plasma cell infiltrate on liver biopsy. He was successfully treated with steroids and daratumumab, an anti‐CD38‐monoclonal antibody. The dramatic response in this patient warrants expanded investigation of daratumumab for plasma cell‐mediated disorders post‐HCT. It further highlights that identifying mechanisms of immune‐mediated injury can allow for directed therapy and limit exposure to broad immune suppression.